Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26978426 | 1.00 | MRGPRX1 (0.62) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL26978352 | 0.89 | SMN1; SMN2 (0.51) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL26980589 | 0.86 | MRGPRX1 (0.59) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL29689010 | 0.86 | MRGPRX1 (0.59) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL30700902 | 0.85 | MRGPRX1 (0.50) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL26978261 | 0.85 | MRGPRX1 (0.50) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL29688906 | 0.84 | MRGPRX1 (0.62) | MRGPRX1SMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL26978108 | 0.84 | MRGPRX1 (0.62) | MRGPRX1SMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL24499970 | 0.83 | MRGPRX1 (0.61) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL29689334 | 0.83 | MRGPRX1 (0.61) | MRGPRX1SMN1; SMN2LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| EP-4255893-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | The Johns Hopkins University (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022119823-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | MRGPRX1, MRGPRX4, MRGPRX2 | MRGPRX1 1/4885SMN1; SMN2 979/4885LMNA 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.